JPRN-jRCT2080221737
Unknown
Phase 3
A Phase III Clinical Trial of Duloxetine in Participants With Fibromyalgia
ConditionsFibromyalgia
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Fibromyalgia
- Sponsor
- SHIONOGI & CO., LTD.
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Participants fulfilling the criteria in the American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. And et al.
Exclusion Criteria
- •Participants with past history of multiple episodes of drug allergy.
- •Participants previously treated with duloxetine.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Unknown
Phase 3
A phase 3 clinical trial of duloxetine in patients with osteoarthritisJPRN-jRCT2080222625Shionogi & Co., Ltd.
Unknown
Phase 3
A phase 3 clinical trial of duloxetine in patients with chronic low back paiChronic low back painJPRN-jRCT2080222083SHIONOGI & CO., LTD.
Unknown
Phase 4
A Study of Duloxetine (LY248686) in Participants With Diabetic Peripheral Neuropathic PaiDiabetic Peripheral Neuropathic PainJPRN-jRCT1080222824Shionogi & Co., Ltd.
Completed
Phase 3
A phase 3 clinical trial of duloxetine in children and adolescents with depressive disorderJPRN-jRCT2080223678Shionogi & Co., Ltd.149
Completed
Not Applicable
effect of Duloxetine in treatment of ADHDAttention Deficit Hyperactivity Disorder(ADHD).Attention deficit: disorder with hyperactivity hyperactivity disorder syndrome with hyperactivityIRCT2012072210363N1niversity of Social Welfare and Rehabilitation Sciences10